Fujifilm shares fall after report Avigan not showing clear efficacy in some coronavirus trials By Reuters
TOKYO (Reuters) – Shares of Fujifilm Holdings Corp (T:) fell on Wednesday after Kyodo news reported that so far there has been no clear evidence of efficacy for its drug Avigan in treating the novel coronavirus in some clinical trials.
The data reported to Japan’s health ministry by hospitals treating people showing mild or no symptoms raises doubts about whether the drug can be approved by the end of this month as sought by Japan’s government, the report said, citing unidentified sources.
The government has not changed its plans to promptly seek approval for Avigan if its efficacy and safety can be confirmed, Chief Cabinet Secretary Yoshihide Suga said on Wednesday.
Fujifilm spokeswoman Kana Matsumoto said the company was not involved in the clinical research conducted mainly at Fujita Health University or other observational studies.
“Fujifilm is not aware of, nor in a position to comment on the